Bentonville, Arkansas 72712

  • Electronic Cigarette Use


The study will assess product use behaviors, biomarkers of exposure, subjective effects, and safety in smokers who switch to a RELX ENDS over 8-weeks.


Inclusion Criteria: 1. Provides voluntary consent to participate in the study as documented on the signed informed consent form (ICF). 2. Is 22 to 65 years of age, inclusive, at the time of consent. 3. Is willing to comply with the requirements of the study. 4. Reports typically smoking 5 or more combustible CPD at Screening. 5. Has been a daily smoker for at least 12 months prior to Screening. Brief periods of non-smoking (e.g., up to ~7 consecutive days due to illness, trying to quit, participation in a study where smoking was prohibited) ≥ 56 days prior to Screening will be permitted at the discretion of the Investigator. 6. Has a positive urine cotinine test (≥ 200 ng/mL) at Screening and Test Visit 1. 7. Has an exhaled carbon monoxide (ECO) value > 10 ppm at Screening and Test Visit 1. 8. Has daily access to a cell phone for daily product use reporting. 9. If female, meets one of the following criteria: If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first product use and during the study. An acceptable method of contraception includes one of the following: - Abstinence from heterosexual intercourse - Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch) - Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses), as confirmed by follicle stimulating hormone (FSH) levels. Exclusion Criteria: 1. Has a history or presence of clinically significant uncontrolled gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. 2. Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, electrocardiogram (ECG), or clinical laboratory results, in the opinion of the Investigator. 3. Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at Screening. 4. Has a positive COVID-19 test at Screening or during the study. 5. Has had an acute illness (e.g., upper respiratory infection, viral infection) within 14 days prior to Test Visit 1. 6. Has a fever (> 100.5°F) at Screening or Test Visit 1. 7. Has a body mass index (BMI) greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Screening. 8. Has a systolic blood pressure < 90 mmHg or > 150 mmHg, diastolic blood pressure < 40 mmHg or > 95 mmHg, or heart rate < 40 bpm or > 99 bpm at Screening. 9. Has a post-bronchodilator forced expiratory volume in 1 second:forced vital capacity (FEV1:FVC) ratio < 0.7 and FEV1 < 50% of predicted at Screening. 10. Has a post-bronchodilator FEV1 increase ≥ 12% and > 200 mL from pre- to post-bronchodilator at Screening. 11. Has used an ENDS product on >7 days during each of the 3 months prior to Screening or any use from Screening to Test Visit 1 other than as may be required for this study. 12. Reports use of a very-low nicotine content cigarette (e.g., Moonlight, Spectrum, VLN) as usual brand. 13. Has used nicotine-containing products other than manufactured cigarettes (e.g., ENDS products (e-cigarettes), roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 14 days prior to Test Visit 1. 14. Has used any products for the purpose of smoking cessation, including, but not limited to, nicotine replacement therapies, varenicline (Chantix), or buproprion (Zyban) from 30 days prior to Screening through the duration of the study. 15. Is a self-reported puffer (i.e., draws smoke from the cigarette into the mouth and throat but does not inhale). 16. Is postponing a planned smoking quit attempt in order to participate in the study. 17. Has a history of drug or alcohol abuse within 12 months prior to Screening, as determined by the Investigator. 18. Is allergic to PG or glycerin. 19. Has a positive urine drug or alcohol breath test at Screening or Test Visit 1. At the discretion of the investigator, a subject testing positive for tetrahydrocannabinol may be permitted to participate if the subject reports use by routes other than inhalation. 20. If female, the subject is pregnant, breastfeeding, or intends to become pregnant from Screening through the duration of the study. 21. Has been treated for depression, diabetes, asthma, emphysema, or chronic obstructive pulmonary disease within 12 months prior to Test Visit 1. 22. Has previously been diagnosed with any form of cancer, except for basal cell or squamous epithelial carcinomas of the skin that have been resected at least 12 months prior to Screening 1. 23. Has a planned surgery that would occur during study participation. 24. Has participated in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to Test Visit 1. 25. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a current or former employee of a tobacco or ENDS manufacturer or is a named party or class representative in litigation with the tobacco or ENDS industry. 26. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a current employee of the clinic site. 27. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a current employee of the Sponsor. 28. Has previously taken part in (from completion of any baseline measurements), has been withdrawn from, or has completed this study. 29. In the opinion of the Investigator, the subject should not participate in this study.



Primary Contact:

Study Director
Donald Graff, PharmD
Sponsor Representative

Donald Graff, PharmD
Phone: 402-326-0541

Backup Contact:


Location Contact:

Bentonville, Arkansas 72712
United States

Richard Lally
Phone: 479-367-2688

Site Status: Recruiting

Data Source:

Date Processed: July 31, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.